Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
MEDI0680 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MEDI0680||AMP-514|AMP514|MEDI-0680||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68||MEDI0680 (AMP-514) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 31439037).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||MEDI0680||Phase I||Actionable||In a Phase I trial, treatment with MEDI0680 (AMP-514) was well-tolerated and demonstrated safety, and resulted in a clinical response in 14% (8/58) of patients with advanced solid tumors, including 5 patients with kidney cancer, with one complete response, and 3 patients with melanoma (PMID: 31439037).||31439037|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02013804||Phase I||MEDI0680||A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies||Completed||USA||0|